FHTX (Foghorn Therapeutics) PB Ratio: (As of Aug. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FHTX Foghorn Therapeutics Inc FHTX
67 GF Score
Price $6.69
GF Value $5.32
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Foghorn Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-26), Foghorn Therapeutics's share price is $6.69. Foghorn Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 was $-1.38. Hence, Foghorn Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Foghorn Therapeutics's PB Ratio or its related term are showing as below:

During the past 8 years, Foghorn Therapeutics's highest PB Ratio was 2903.33. The lowest was 2.85. And the median was 6.43.

FHTX's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.975
* Ranked among companies with meaningful PB Ratio only.

Back to Basics: PB Ratio


Foghorn Therapeutics  (NAS:FHTX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Foghorn Therapeutics PB Ratio Related Terms


Foghorn Therapeutics PB Ratio Historical Data

* Premium members only.

The historical data trend for Foghorn Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Foghorn Therapeutics PB Ratio Chart

Foghorn Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial 9.75 2,126.67 0.00 0.00 0.00

Foghorn Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FHTX vs NWBO, FATE, IMRX: PB Ratio Comparison

For the Biotechnology subindustry, Foghorn Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Foghorn Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Foghorn Therapeutics's PB Ratio falls into.


FHTX
67GF Score
Foghorn Therapeutics Inc FHTX
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Foghorn Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Foghorn Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2026)
=6.69/-1.38
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Foghorn Therapeutics (FHTX) Overvalued in 2026?

Based on GuruFocus' analysis, Foghorn Therapeutics stock appears to be overvalued. The current stock price of $6.69 is trading 25.8% above its estimated GF Value™ of $5.32. GuruFocus considers Foghorn Therapeutics to be Modestly Overvalued.

Key valuation signals for FHTX:

  • PB Ratio:
  • GF Value™: $5.32 vs. price of $6.69 (25.8% above fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the FHTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Foghorn Therapeutics Business Description

Address 99 Coolidge Avenue, Suite 500, Watertown, MA, USA, 02472
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
67GF Score

Get the complete analysis for FHTX

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.69
Price
$5.32
GF Value